Pictured: Jedd Wolchok
MSK at ASCO
By Media Staff  |  Wednesday, June 4, 2014

Our experts offer their perspective in major media outlets on recent research into drug- and cell-based immunotherapies for cancer.

Pictured: Helen McArthur
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, June 3, 2014

The treatment combines a technique called cryoablation, or freezing of the tumor, with an immunotherapy drug.

Pictured: Jedd Wolchok
In the News
By Jim Stallard, MA, Writer/Editor  |  Friday, May 2, 2014

Memorial Sloan Kettering physician-scientist Jedd Wolchok describes striking advances in cancer immunotherapy in New York Times and Scientific American.

Pictured: Renier Brentjens, Isabelle Rivière & Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, February 20, 2014

A new study evaluating a cell-based immune therapy to treat an aggressive type of leukemia — the largest study of its kind to date — reports that 88 percent of patients responded to the treatment.

Pictured: T cells
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 23, 2013

Memorial Sloan Kettering researchers have played a major role in cancer immunotherapy research, named “Breakthrough of the Year” by Science magazine.

Pictured: Jedd Wolchok & Richard Carvajal
In the Clinic
By Media Staff  |  Monday, June 3, 2013

Two Memorial Sloan Kettering studies that hold promise for the treatment of advanced uveal (eye) melanoma and advanced skin melanoma are making headlines at the 49th Annual Meeting of the American Society of Clinical Oncology.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, April 4, 2013

Early research led by investigators at Memorial Sloan Kettering cautions against combining ipilimumab and vemurafenib for the treatment of metastatic melanoma.

Pictured: Isabelle Rivière, Michel Sadelain & Renier Brentjens
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Wednesday, March 20, 2013

Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.

Pictured: ESK1 Monoclonal Antibody
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 13, 2013

Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Pictured: Michel Sadelain
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Tuesday, December 18, 2012

Memorial Sloan Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.

Pictured: Ming Li
Q&A
By Eva Kiesler, PhD, Science Writer/Editor  |  Friday, December 14, 2012

Recent findings by Memorial Sloan Kettering immunologists might one day pave the way for new strategies to control a range of diseases, including autoimmune disorders and cancer.

Pictured: Michel Sadelain & Jedd Wolchok
Announcement
By Media Staff  |  Wednesday, December 12, 2012

Physician-scientists Michel Sadelain and Jedd Wolchok have been appointed to a new research team dedicated to investigating ways to harness the immune system to fight cancer.

Pictured: Isabelle Rivière and Michel Sadelain
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Monday, July 16, 2012

Memorial Sloan Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

Pictured: Jedd Wolchok and James Allison
In the News
By Media Staff  |  Friday, April 20, 2012

In an article describing the history and promise of immunotherapy for cancer treatment, the magazine highlights the groundbreaking work of James Allison, Chair of the Sloan Kettering Institute’s Immunology Program, and medical oncologist and immunologist Jedd Wolchok.

Pictured: Jedd Wolchok
In the Clinic
By Media Staff  |  Thursday, March 8, 2012

Findings from a multidisciplinary research team led by Memorial Sloan Kettering medical oncologist and immunologist Jedd Wolchok could help shed light on the immune system’s role in fighting cancer.

Center News

Stay Informed

Get the latest information about cancer care and research every month.